**The role of exercise in limiting progression from liver inflammation and fibrosis to cirrhosis and carcinoma: a systematic review with meta-analysis of human and animal studies**  4 Stanhope, E.N.,<sup>1,2</sup> Drummond, A.E.,<sup>3</sup> Swain, C.T.V.,<sup>3,4</sup> Teoh, N.,<sup>5</sup> Farrell, G.,<sup>5</sup> Vallance, J.K.,<sup>6</sup> 5 Lahart, I.M. $^{2*}$  Lynch, B.M.<sup>3,7\*</sup> **Institutions** 1. School of Health, Science and Wellbeing, Staffordshire University, United Kingdom. 2. Faculty of Education, Health and Wellbeing, University of Wolverhampton, United Kingdom. 3. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia. 4. Department of Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, Australia. 5. Gastroenterology and Hepatology Unit, The Canberra Hospital and The Australian National University, Canberra, Australia. 6. Faculty of Health Disciplines, Athabasca University, Athabasca, Canada. 7. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Australia. \* joint senior authors **Corresponding author**  Edward N. Stanhope. School of Health, Science and Wellbeing, Staffordshire University, United Kingdom. edward.stanhope@staffs.ac.uk **Abstract** Background: Exercise may prevent the progression of liver disease and protect against liver cancer. This review with meta-analysis synthesised the evidence from both human and animal studies to better understand whether exercise has the capacity to (i) promote regression of early fibrosis; (ii) decrease and/or delay progression to cirrhosis; and (iii) progression to carcinoma.



NAFLD, NASH, HCC, HBV, HCV, Physical activity

#### **Introduction**

Liver disease is a growing concern worldwide with rising incidence rates irrespective of age, sex, region, or ethnicity (1). The global prevalence of non-alcoholic fatty liver disease (NAFLD) has been estimated to be between 20% and 30% in adults (2), of which ~20% have non-alcoholic steatohepatitis (NASH) (3). The term NAFLD encompasses a continuum of liver pathologies, ranging from non-alcoholic fatty liver (NAFL) to cirrhosis and hepatocellular carcinoma (HCC) (4). Simple steatosis with minimal inflammation (NAFL) is relatively benign and has a much lower risk of disease progression than patients with active inflammation (NASH) (5,6). However, once liver fibrosis is present the risk of disease progression and liver-related complications increases dramatically (7) and the chance of developing HCC is seven times greater than that of patients without liver disease (8).

According to the World Health Organisation (WHO, 2020), the progression from acute hepatitis B virus (HBV) to chronic HBV is relatively rare, affecting less than 5% of cases. People with chronic HBV infection, however, face a notable lifetime risk of developing cirrhosis or liver cancer (15% to 40%) (9). Conversely, the transition from acute hepatitis C virus (HCV) to chronic HCV is more common. This transition is observed in 55% to 85% of people with HCV, with approximately 15% to 30% of these people progressing to cirrhosis. In both the case of HBV and HCV, the prognosis for people who develop liver cirrhosis or HCC is considerably 69 worse  $(10-12)$ . Given that HCC is the third leading cause of cancer-related deaths worldwide (12), and approximately 90-95% of people with HCC have underlying liver cirrhosis (13), the progression from liver cirrhosis to HCC is a matter of great concern.

The liver is one of only a few organs that can regenerate. Its regeneration capacity, however, is finite. If there is insufficient availability of hepatocytes, liver disease can become irreversible

with severe consequences, such as increased sensitivity to noxious substances (encephalopathy), increased risk of gastrointestinal (GI) bleeding (varices and coagulopathy), and decreased bile flow (14).

Lifestyle modification, such as increasing physical activity, may help improve liver disease outcomes. Emerging evidence suggests that increasing physical activity may enhance liver repair, reduce the risk of liver diseases, such as NAFLD and liver cancer, and slow the progression from HBV, HCV, NAFLD, and alcohol-related liver disease to liver cirrhosis and HCC (11,12). Whereas the epidemiological evidence suggests a protective effect of increased physical activity against liver cancer, the experimental evidence remains inconclusive—largely due to factors such as heterogeneity in the assessment of 'exposure'—which limits support for exercise intervention in treating liver disease (15).

Examining the evidence for the biological plausibility of exercise reducing the risk of liver disease can provide support for causal inference. Preclinical studies indicate that, if hepatic steatosis can be reversed through exercise intervention, then liver inflammation and fibrosis can 88 be resolved (4). Due to the invasive nature of liver biopsy, much of the mechanistic evidence for the effects of exercise on liver disease comes from animal studies. However, in vivo animal studies suggest liver fibrosis is more susceptible to regeneration in animals compared to humans (16), and therefore species-specific liver regeneration differences cannot be ruled out (17). Hence, to ensure translation, human mechanistic studies must also be examined.

Developing a better understanding of how exercise affects intermediate biological processes may provide insight into the best ways to alter exposures for disease prevention. The overarching objective of this review is to improve the understanding of whether exercise has the capacity to

(i) promote regression of early fibrosis, (ii) decrease or delay progression to cirrhosis; and (iii)

- progression to carcinoma.
- **Methodology**
- **Study Design**
- This was a systematic review and meta-analysis of human and animal studies.

#### **Search Strategy**

Relevant publications were identified using tailored search strategies of MEDLINE (via Ovid) from 1946 - June 27, 2021, EMBASE (via Ovid) from 1974 - June 27, 2021, and SportDiscus (via EBSCO) from 1985 - July 4, 2021. The tailored search strategies used a combination of medical subject headings and free text terms. A version of the search strategy for MEDLINE is presented in Appendix 1. Searches were performed on June 29, 2020, and updated on July 22, 2021.

#### **Eligibility criteria**

Both human and animal studies published in peer-reviewed journals were eligible for inclusion.

Only studies published in English were included. Conference abstracts were excluded.

We included human studies with parallel group randomized controlled trials (RCTs) and randomized crossover trials (RXTs) designs, whereas non-randomized interventions and observational studies were excluded due to their lower level of evidence for establishing causal effects. Participants included adults (>18 years old) with liver inflammation (including NAFL and NASH) or fibrosis. Populations with other clinically relevant health conditions (e.g.,

metabolic syndrome, type II diabetes) were also considered. Acceptable interventions included any exercise intervention that disturbed the bodies homeostasis through muscular activity, whether exclusively concentric, eccentric, or isometric, or a combination thereof (18). We considered studies that offered general dietary recommendations in addition to exercise but excluded studies that combined exercise and dietary interventions (e.g., caloric restriction). We excluded studies if the effects of exercise could not be isolated and if the period of exercise was less than seven days. We included studies that contained at least one control arm that did not receive exercise.

Regarding animal studies, we included parallel randomized controlled trials involving genetic and induced models of liver disease; induction methods included, but were not limited to, exposure to diet and alcohol. We excluded single-group pre-post intervention studies and those lacking a non-exercise period for NAFLD induction or a non-exercise induction period which lasted less than eight weeks, as it is improbable to induce NAFLD within such a short timeframe (19,20). Eligible interventions included any form of exercise as defined by Winter & Fowler (2009). We excluded studies if the effects of exercise could not be isolated (e.g., exercise and caloric restriction). To be considered for inclusion, the period of exercise intervention must have been greater than seven days and studies were required to have at least one control group that did not receive exercise.

We included studies that used invasive or non-invasive procedures to determine whether i) inflammation or fibrosis had reverted to an earlier stage of the disease or resolved; (ii) progressed to cirrhosis; (iii) and/or progressed to carcinoma.

The gold standard for evaluating liver fibrosis, cirrhosis, and carcinoma (cancer) is a liver biopsy, whereby a small tissue sample from the liver is extracted for microscopic examination, enabling the assessment of fibrosis (scarring), cirrhosis (advanced scarring), and the presence of carcinoma or cancerous cells. However, liver biopsy is an invasive procedure that may have 147 some risks associated with it, such as bleeding or infection. As a result, non-invasive methods, including FibroScan (Transient Elastography), blood tests, magnetic resonance elastography (MSE), shear wave elastography (SWE), fibrosis blood panels and other imaging modalities (i.e., CT and MRI) have been developed and were included in our review.

#### **Selection of studies**

Study eligibility was judged against the pre-defined inclusion and exclusion criteria. Two authors (ES, IML) independently screened the titles and abstracts of articles for eligibility. In cases of disagreement the two authors discussed each case and tried to reach a consensus. If a consensus could not be reached a third reviewer was consulted (BL). If inadequate information was available in the title and abstract to determine eligibility it was included for next stage (full text) review. The same two authors (ES, IML) independently reviewed the full text of articles that were included based on the title and abstract screening. In cases where there was disagreement about the eligibility of an article, the two authors aimed to reach a consensus. If a consensus could not be reached a third reviewer (BL) was consulted. The authors were not blind to study authors, journals, or results. A screening log was maintained and the number of excluded studies and their reason for exclusion recorded.

### **Data extraction**

Data extraction for human studies was performed by ES and IML using a pre-piloted system, whereby one author extracted data into a table, and another validated the data extraction. Data extraction for animal studies was performed in the same way by BL and AD. Extracted data included study details (e.g., authors, year), study design, population (e.g., sample size, demographic information, health status), intervention details (e.g., duration, exercise frequency, intensity, time, type), comparator conditions, outcome details (e.g., definition, assessment method), and statistical measures (e.g., post-intervention means and standard deviation). The Webplot digitiser was used to extract data from studies that exclusively presented their results in graphical form.

#### **Data synthesis and meta-analysis**

Extracted data were summarised and presented descriptively. For outcomes that were consistently defined and reported in at least three studies, random effects meta-analysis was used to estimate the effects of exercise on liver outcomes. Meta-analysis compared post-intervention means and standard deviation between intervention and control groups. When studies had more than one intervention group that met the criteria for inclusion, post-intervention means and standard deviations were combined as per the Cochrane Collaboration manual (21). Meta-analysis effect estimates are presented as standardised mean difference (SMD) and 95% 184 confidence interval (95%CI). Heterogeneity was assessed using the  $I^2$  statistic. Publication bias was assessed via visual inspection of funnel plots. For animal studies, meta-regression was used to assess the influence of study year, study location (i.e., region), animal type, disease, and disease inducement method on effect estimates. For human studies, meta-regression was used to



**Results** 

#### **Identification of studies**

Search results are presented in Figure 1. Of the 1,535 records identified via database search, 1,352 titles and abstracts were screened, and 174 full texts were assessed for eligibility, with 60 full texts meeting all criteria for inclusion. Of these, there were 29 interventions in animals and 18 interventions conducted in humans.

### **Study characteristics**

Study characteristics of human studies are presented in Table 1. Studies were conducted in Asia 201 (animal = 6, human = 4), Australia (human = 1), Europe (animal = 8, human = 6), the Middle 202 East (animal  $= 3$ , human  $= 3$ ), North America (animal  $= 9$ , human  $= 1$ ), or South America 203 (animal  $= 4$ , human  $= 1$ ). A total of 1,976 participants with a median (IQR) sample of 47 (27– 135). There was a slightly higher proportion of male compared to female participants across 205 studies (median  $\% = 52\%$  vs. 48%); two studies included only female participants (22,23). The median (IQR) average age was 53 (49–55) years and median (IQR) average BMI was 32 (30–33) 207  $kg/m^2$ .

- 209 The type of liver disease studied included NAFLD (animal  $= 17$ , human  $= 14$ ), NASH (animal  $=$
- 210 5, human = 1), hepatic steatosis (animal = 4), liver cirrhosis (human = 1), liver fibrosis (animal =

- 211 1), polycystic liver disease (animal  $= 1$ ), metabolic syndrome (human  $= 1$ ), type II diabetes 212 (human = 1), and extrahepatic obstruction (animal = 1).
- 213

All but one (24) of the human studies provided details on how NAFLD was diagnosed. NAFLD diagnosis methods in human studies included: proton magnetic resonance spectroscopy (MRS) alone (25–27), ultrasonography alone (22), MRS and ultrasonography (28), ultrasonography and elevated alanine aminotransferase (ALT) (29), Asia Pacific Working Party guidelines (30,31), liver biopsy (23), and controlled attenuation parameter (CAP) measurements performed via vibration-controlled elastography (VCTE) (32). Liver biopsies were used to diagnose NASH in the only study that consisted of patients diagnosed with this condition (33). Whereas, in one study (34) a variety of measures were used to diagnose liver cirrhosis (computed tomography, MRI, transient elastography, or liver biopsy).

223

224 Human studies had one (N = 13), two (N = 4), or three (N = 1) intervention arms that were 225 relevant to this review. The interventions included only moderate-intensity continuous training 226 (N = 8), resistance training (N = 4), high-intensity interval training (N = 2), moderate-intensity 227 continuous training combined with resistance training  $(N = 4)$ , vigorous-intensity training  $(N = 1)$ 228 1), or physical activity guidelines and counselling support  $(N = 1)$ . The comparison conditions 229 included a no intervention control ( $N = 7$ ), standard care ( $N = 3$ ), general diet and/or physical 230 activity advice (N = 3), a wait-list control (N = 1), placebo supplement (N = 1), control diet (N = 231 1), or stretching  $(N = 1)$ .

Study characteristics of animal studies are presented in Table 2. Animal studies included an approximate total of 992 animals and had a median [inter-quartile range (IQR)] of 32 (24–39), although it was not possible to discern the exact number due to study reporting quality (e.g., a study may have reported '7–8' mice per group). There were 17 studies with rats and 12 studies with mice.

238

239 In animal studies, these diseases were induced via diet  $(N = 22)$ , genetic phenotype  $(N = 6)$ , or 240 drug induced (N = 1). Animal studies had either one (N = 17) or two (N = 12) intervention arms 241 relevant to this review. Interventions in animal studies included continuous exercise (e.g., 242 treadmill running,  $N = 24$ ), voluntary exercise (e.g., voluntary wheel running,  $N = 8$ ), or 243 swimming  $(N = 5)$ .

244

245 Only one study (human = 1) directly reported the number of NAFLD participants who 246 experienced disease regression, reduction, or progression. In most studies, liver function and/or 247 damage were used as surrogate markers for remission and progression, and included tests for 248 liver enzymes: alanine transaminase (ALT) (animal  $= 18$ , human  $= 16$ ), aspartate transaminase 249 (AST) (animal = 11, human = 15), alkaline phosphatase (ALP) (animal = 2, human = 4), and 250 gamma-glutamyl transferase  $(GGT)$  (animal = 1, human = 12).

251

252 The assessment of liver triglyceride content included hepatic triglyceride content (HTGC) 253 (animal = 9), intrahepatic triglyceride content (IHTG) (human = 1), HTGC/IHTG (human = 5), 254 liver fat percentage (human = 3), intra-hepatocellular lipid (IHCL) (human = 1), liver lipid

255 percentage (animal  $= 1$ ), intrahepatic lipid content (IHL) (human  $= 4$ ), liver triacylglycerol 256 (TAG) (animal = 5), and hepatic fat content (HFC) (human = 1).

257

258 For the evaluation of liver steatosis and related measures, the fatty liver index (human = 1), 259 ferritin (human  $= 4$ ), fetuin A (human  $= 1$ ), hepatic steatosis (human  $= 2$ ), NAFLD (non-260 alcoholic fatty liver disease) (human  $= 1$ ), NAFLD activity score (NAS) (animal  $= 5$ ), fibrosis 261 score (animal  $= 1$ , human  $= 2$ ), and steatosis score (animal  $= 3$ ) were included.

262

263 Additionally, other liver outcome measures were taken into account, such as liver droplet size 264 (animal  $= 4$ ), liver stiffness (human  $= 2$ ), spleen stiffness (human  $= 1$ ), liver diacylglycerol 265 (DAG) (animal = 3), hepatorenal index (HRI) (human = 1), liver platelets (PLT) (human = 1), 266 hepatic tuberculosis (TB) (human  $= 1$ ), liver weight (animal  $= 6$ ), and vascular endothelial 267 growth factor (VEGF) (human  $= 1$ ).

268

### 269 **Liver disease regression and/or progression**

270 In our review, only one study (25) directly investigated the impact of exercise on the remission 271 or progression of NAFLD. The findings revealed that  $14\%$  (n = 3/22) of participants assigned to 272 the exercise group achieved a decrease in hepatic fat content (HFC) to less than 5.6% (normal 273 levels), while this was observed in only 11% ( $n = 2/18$ ) of those who received no intervention. 274 Moreover, 54% ( $n = 12/22$ ) of the exercise group experienced a reduction in HFC, while only 275 17% ( $n = 3/18$ ) in the no intervention group showed a similar improvement. Furthermore, 276 elevated HFC was observed in only 32% ( $n = 7/22$ ) of participants in the exercise group, 277 compared to 72% ( $n = 13/18$ ) in the no intervention arm. These findings suggest a positive

association between exercise intervention and the regression of early fibrosis, as well as a delay in the progression to cirrhosis. We found no studies that directly evaluated the progression to HCC.

## **Markers of liver function and damage**

Meta-analysis of human studies was possible for outcomes ALT, AST, ALP, GGT, and hepatic triglyceride content only (Figure 2). Meta-analysis of animal studies was possible for outcomes ALT, AST, NAS, and liver triglycerides only (Figure 3). We conducted separate meta-regression analyses for human (Supplementary Table 1) and animal studies (Supplementary Table 2). In human studies, we accounted for year, region, disease, and study type. Meanwhile, in animal studies, we controlled for year, region, animal type, disease, and inducement. Results of meta-regression and funnel plots are presented in supplementary material. Results of individual studies not included in the meta-analyses are presented in supplementary table 3 and 4.

#### **Liver enzymes**

Meta-analysis of studies that assessed the effects of exercise on ALT are presented in Figure 2A (human studies) and Figure 3A (animal studies). In the human studies, participants who were assigned to the exercise group exhibited a modest reduction in ALT levels compared to those in 296 the control group (Studies = 12, N = 1,209, SMD =  $-0.28$ , 95%CI =  $-0.53$ ,  $-0.03$ ). Moreover, in animal studies, a greater difference in ALT levels was observed between the exercise and control 298 groups (Studies = 15, N = 274, SMD = -2.61, 95%CI = -3.91, -1.30). Heterogeneity was 299 considerable in animal studies ( $I^2 = 94\%$ ) and substantial in human studies ( $I^2 = 65\%$ ). Some of the heterogeneity in the animal studies could be explained by animal type, with higher effect

estimates observed for studies with rats compared to mice (Supplementary Table 2). Funnel plots suggested likely publication bias in animal studies but not for human studies (Supplementary Figure 1). Additional individual studies not included in the meta-analysis reported either a statistically significant reduction in ALT following intervention compared to the control group (35) or no statistically significant difference (28,36) (Supplementary Table 3).

Meta-analysis of studies that assessed the effects of exercise on AST are presented in Figure 2B (human studies) and Figure 3B (animal studies). Participants assigned to the intervention showed a slight difference in AST compared to the control group, favouring the intervention (Studies = 310 10, N = 1,148, SMD = -0.12,  $95\%CI = -0.32$  to 0.07). However, the certainty of this finding was limited by confidence intervals that crossed the null. Additionally, animals assigned to the exercise intervention demonstrated a significant difference in AST compared to the control group 313 (Studies = , N = 146, SMD = -2.88, 95%CI = -4.78 to -0.98). Heterogeneity was considerable in 314 animal studies ( $I^2 = 95\%$ ) and moderate in human studies ( $I^2 = 39\%$ ). Funnel plots suggested likely publication bias in animal studies but not in human studies. Meta-regression results are presented for human (Supplementary Table 1) and animal studies (Supplementary Table 2) in the supplementary materials. Some of the heterogeneity in the human and animal studies meta-analysis was explained by study region. Furthermore, in the animal studies, study year explained some of the heterogeneity in the meta-analysis. Individual studies that were not included in the meta-analysis identified a statistically significant reduction in AST in the intervention compared to control arm following intervention (35) or no statistically significant difference (28,36) (Supplementary Table 3).

Meta-analysis of human studies that assessed the effects of exercise on ALP are presented in Figure 2C. Despite the confidence intervals crossing the null, our analysis revealed a small increase in ALP among those assigned to exercise when compared with the control group 327 (Studies = 3, N = 130, SMD = 0.23, 95% CI =  $-0.13$ , 0.59). There was no evidence of 328 heterogeneity ( $I^2 = 0\%$ ), nor was there evidence of publication bias. Meta-regression was not possible for ALP in either human or animal studies. Two individual animal studies examined the effects of exercise on ALP, both found a decreases in ALP for exercise compared to control (37,38) (Supplementary Table 4).

Meta-analysis of human studies that assessed the effects of exercise on GGT are presented in Figure 2D. There was a small decrease in GGT in participants receiving exercise intervention 335 compared to controls (Studies = 10, N = 1,142, SMD =  $-0.23$ , 95%CI =  $-0.36$ ,  $-0.10$ ). 336 Heterogeneity was low  $(I^2 = 6\%)$  and there was no clear evidence of publication bias (Supplementary Figure 1). There were no statistically significant findings from the meta-regression (Supplementary Table 1). In three individual studies not included in the meta-analysis, two (35,36) identified decreases in GGT following exercise relative to control (Supplementary table 3). One study (28) did not identify definitive differences between exercise and control groups. There was no difference in GGT between groups in one animal study (39) (Supplementary Table 4).

**Liver triglyceride content** 

Meta-analysis of human studies that assessed the effects of exercise on HTGC are presented in Figure 2E. Participants assigned to exercise showed, on average, HTGC compared to the control 348 group (Studies = 3, N = 101, SMD =  $-0.24$ , 95%CI =  $-0.66$ , 0.18). However, it's worth noting 349 that the confidence intervals overlapped the null value. Heterogeneity was low ( $I^2 = 0\%$ ) and there was no clear evidence of publication bias (Supplementary Figure 1). Meta-regression was not possible for HTGC in human studies. The percentage decrease in HTGC was greater following moderate and high intensity exercise compared to control in one individual human study not included in the meta-analysis (28). There was no difference between moderate and high intensity exercise.

Meta-analysis of animal studies that assessed the effects of exercise on liver triglycerides are presented in Figure 3D. There was a large difference in liver triglycerides between exercise and 358 control groups (Studies = 10, N = 172, SMD = -1.94,  $95\%CI = -3.87, 0.00$ ). Heterogeneity was, 359 however, considerable ( $I^2 = 96\%$ ) and there was evidence of publication bias (Supplementary Figure 2). Meta-regression indicated that some of the heterogeneity could be explained by animal type—with larger effect estimates observed for studies that used rats—but not by year, region, disease, or inducement (Supplementary Table 2). Individual animal studies not included in the meta-analysis suggested lower liver triglycerides for exercise compared to control (40).

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), individual studies suggested that exercise can decrease liver TAG (41–43), HFC (25), the fatty liver index (44), IHCL (45), and IHL (24,46).

#### **Liver steatosis and related measures**

Meta-analysis of all four animal studies that assessed the effects of exercise on NAS are presented in Figure 3C. There was a large decrease in NAS with exercise versus control (Studies 372 = 4, N = 98, SMD = -1.36, 95%CI = -2.08, -0.65). Heterogeneity was substantial ( $I^2$  = 59%) and there was some evidence of publication bias (Supplementary Figure 2). Meta-regression of NAS was not possible and therefore, the heterogeneity observed remained unexplained.

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), the findings on Ferritin were mixed in the literature; two studies (35,36) reported a decrease with exercise compared to controls, while two other studies (23,31) found no statistically significant difference. Similarly, one study (47) observed differences in fibrosis score between exercise and control groups, while another (33) did not find any distinction.

#### **Other relevant liver outcome measures**

Meta-analysis of all six animal studies that assessed the effects of exercise on liver weight are presented in Figure 3E. There was a large difference in liver weight between exercise and control 385 groups (Studies = 6, N = 144, SMD = -1.94,  $95\%CI = -2.78$ , -1.10). Heterogeneity was 386 considerable ( $I^2 = 77\%$ ), although could not clearly be explained by factors included in the meta-regression analysis (Supplementary Table 2). There was possible publication bias evident in the funnel plots (Supplementary Figure 2).

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), individual studies suggested that exercise can decrease liver DAG (42,48), hepatic stiffness (31) and HRI (36). There were null findings for liver stiffness (34), spleen stiffness (34), and VEGF (23).

#### **Discussion**

This current review synthesized the evidence for the effect of exercise interventions versus control/standard care on liver function and disease in people and animals with established liver disease. Only one study directly reported whether liver disease (NAFLD) regressed or progressed in response to exercise intervention. Most studies included in this review compared measures of liver function and/or damage between exercise and non-exercise interventions. The findings of these studies support the biological plausibility for a protective effect of exercise on liver function and disease.

The primary strength of this review is the synthesis of findings from both human and animal studies. While there is a wealth of data from animal studies relevant to human health, systematic reviews, which are common practice in clinical and public health research, remain less common in animal research. Animal studies offer a unique advantage in exploring liver outcome measures that are not feasible to obtain through biopsy in humans. However, it is essential to recognize that the responses observed in animals may not always directly translate to human-specific outcomes. On the other hand, human studies heavily rely on surrogate measures of liver function and damage. By incorporating results from both human and animal studies, this review greatly enhances our understanding of the effects of exercise on liver function, as well as the potential translation of animal study findings to human contexts.

This current review also has limitations that should be considered when interpreting the findings. First, we did not perform a risk of bias assessment using a pre-existing risk of bias tool. While tools for assessing study quality in human clinical trials have been modified and applied to animal studies (e.g., SYRCLE), when piloting this tool most animal studies scored poorly simply because the information was not reported.

There was substantial to considerable heterogeneity in the meta-analyses, particularly the meta-analyses of the animal studies, which may limit confidence in the final effect estimates. Sources of heterogeneity present in animal studies that were not present in the human studies included species (e.g., mouse type, rat type) as well as methods used to induce liver disease (e.g., forced feeding, genetic selection). These are in addition to sources of variation present in human studies, such as variations in study design and methods, participant age and sex, exercise type, dose, or duration, and outcome assessment methods. Owing to the studies identified, this review is limited in its ability to examine differing effects for the type and dose of exercise on liver function and/or damage.

Our study's findings indicate that exercise interventions have a positive impact on liver health and function when compared to non-exercise comparison groups. These results align with evidence from epidemiological studies, which have shown that higher levels of physical activity are associated with reduced instances of fatty liver and a decreased risk of liver cancer. For example, in a meta-analysis of observational studies (49), higher (90th percentile) compared to lower (10th percentile) duration of leisure-time physical activity was associated with decreased 431 liver cancer risk (HR =  $0.73$ , 95%CI: 0.55, 0.98). While this epidemiological evidence suggests an association between exercise and outcomes like liver cancer, results from this current review

support the biological plausibility of the findings. That is, exercise may reduce the risk of liver cirrhosis and/or cancer by reducing measures of liver function and/or damage.

Improvement in liver enzymes, liver triglyceride content, and steatosis was evident in both human and animal studies, but the effect estimates were generally larger in the meta-analysis of animal studies compared with the human studies. This may, in part, reflect inter-species differences, with greater potential for liver regeneration in animals. Alternatively, these larger effect estimates may be due to a greater ability to control for sources of variation in animal compared to human studies, who are likely to vary in factors such as intervention adherence, diet, alcohol consumption, body fatness, as well as exercise history and tolerance. Nonetheless, that improvements were present in both humans and animals supports the translation of findings and relevance to people with liver disease.

This current review found an effect of exercise on liver outcomes, but it did not attempt to determine whether these are direct or indirect effects. That is, is the benefit of exercise due to the exercise itself or other factors such as fat loss that may follow exercise participation. Findings from individual studies included within the review suggest at least some of the effects of exercise may be via fat loss (28). However, other studies have proposed mechanisms independent of fat loss, such as facilitating change via the effect of exercise on insulin signalling and serum lipid concentrations, which may lead to an increased ability to suppress lipolysis in adipose tissue, resulting in decreased free fatty acid delivery to the liver (47).

The identification of exercise's impact on liver function and damage provides essential support for the idea that exercise might be linked to liver cancer. As liver cancer is a rare form of cancer, directly examining this relationship presents challenges. Nevertheless, it is important to

emphasize that this discovery is just one step in the broader research pathway. Conducting further research is necessary to delve into how these measures specifically influence the incidence of liver cirrhosis and/or cancer (HCC).

### **Conclusion**

In conclusion, a single investigation focusing on the effect of exercise on the progression and remission of NAFLD revealed a significant association between exercise intervention and the regression of initial fibrosis, as well as a delay in the progression of cirrhosis. Moreover, a comprehensive review of existing literature reveals consistent indications of exercise's positive impact on liver function and reduction of liver damage in both human subjects and animal models with established liver disease. These collective results substantiate the biological plausibility of exercise as a beneficial therapeutic strategy for enhancing liver function and combatting liver disease. Nonetheless, further research and clinical trials are warranted to fully elucidate the mechanisms underlying these observed effects and to establish more robust guidelines for exercise-based interventions in liver disease management.

#### **Acknowledgments**

All authors were involved in conception and design. A. E. D. performed the literature searches, with A. E. D. and J. K. V. selecting articles for exclusion and inclusion, with any disagreement resolved by discussion with B. M. L. Full texts were assessed by E. N. S and I. M. L, with any disagreement resolved by discussion with B. M. L. Data was extracted from human studies by E. N. S. and I. M. L, and from animal studies by A. E. D. and B. M. L. Meta-analysis was conducted by C. T. V. S. All authors contributed to the writing and revision of the manuscript.

## **Conflicts of interest**

- The authors declare no competing interests. No funding was received for this work. The results
- of the study are presented clearly, honestly, and without fabrication, falsification, or
- inappropriate data manipulation.

#### 483 **References**

- 484 1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of Liver Diseases in the World. J 485 Hepatol. 2019 Jan 1;70(1):151–71.
- 486 2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of 487 Nonalcoholic Fatty Liver Disease—Meta-analytic Assessment of Prevalence, Incidence, and<br>488 Outcomes. Hepatology. 2016:64(1):73–84. 488 Outcomes. Hepatology. 2016;64(1):73–84.
- 489 3. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in 490 Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-491 Analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol Off Clin Pract J Am 492 Gastroenterol Assoc. 2015 Apr;13(4):643-654.e1-9; quiz e39-40.
- 493 4. Loomba R, Friedman SL, Shulman GI. Mechanisms and Disease Consequences of 494 Nonalcoholic Fatty Liver Disease. Cell. 2021 May 13;184(10):2537–64.
- 495 5. Day CP. Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis. 496 Gastroenterology. 2005 Jul;129(1):375–8.
- 497 6. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty 498 Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. 499 Transplantation. 2019 Jan;103(1):22–7.
- 500 7. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-501 Term Follow-up of Patients with NAFLD and Elevated Liver Enzymes. Hepatol Baltim Md. 502 2006 Oct;44(4):865–73.
- 503 8. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal Trends of 504 Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs 505 Population. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015 506 Mar;13(3):594-601.e1.
- 507 9. Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, et al. Global 508 Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin 509 Oncol Educ Book. 2018 May 23;(38):262–79.
- 510 10. Czaja AJ. Review Article: The Prevention and Reversal of Hepatic Fibrosis in Autoimmune<br>511 Hepatitis. Aliment Pharmacol Ther. 2014 Feb:39(4):385–406. Hepatitis. Aliment Pharmacol Ther. 2014 Feb;39(4):385-406.
- 512 11. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The Global, 513 Regional, and National Burden of Cirrhosis by Cause in 195 Countries and Territories, 514 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet 515 Gastroenterol Hepatol. 2020 Mar;5(3):245–66.
- 516 12. Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of 517 Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control. 2017 518 Sep 1;24(3):107327481772924.
- 519 13. Forner A, Llovet JM, Bruix J. Hepatocellular Carcinoma. The Lancet. 2012 520 Mar;379(9822):1245–55.

- 521 14. Sharma A, Nagalli S. Chronic Liver Disease. In: StatPearls [Internet]. Treasure Island (FL):
- 522 StatPearls Publishing; 2021 [cited 2021 Jun 28]. Available from:
- 523 http://www.ncbi.nlm.nih.gov/books/NBK554597/
- 524 15. WCRF. Diet, Nutrition, Physical Activity and Liver Cancer. 2015;52.
- 525 16. Desmet VJ, Roskams T. Cirrhosis Reversal: A Duel between Dogma and Myth. J Hepatol. 526 2004 May 1;40(5):860–7.
- 527 17. Cordero-Espinoza L, Huch M. The Balancing Act of the Liver: Tissue Regeneration versus 528 Fibrosis. J Clin Invest. 2018;128(1):85–96.
- 529 18. Winter EM, Fowler N. Exercise defined and quantified according to the Système 530 International d'Unités. J Sports Sci. 2009 Mar 1;27(5):447–60.
- 531 19. Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al. Mouse Models of 532 Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human 533 Nonalcoholic Steatohepatitis. Hepatol Baltim Md. 2019 May;69(5):2241–57.
- 534 20. Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, et al. Mouse Models of 535 Non-Alcoholic Steatohepatitis: A Reflection on Recent Literature. J Gastroenterol Hepatol. 536 2018 Jul;33(7):1312–20.
- 537 21. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions: 538 Cochrane Book Series [Internet]. 1st ed. Wiley; 2008 [cited 2023 Jul 26]. Available from: 539 https://onlinelibrary.wiley.com/doi/book/10.1002/9780470712184
- 540 22. Kelardeh B, Rahmati-Ahmadabad S, Farzanegi P, Helalizadeh M, Azarbayjani MA. Effects 541 of non-linear resistance training and curcumin supplementation on the liver biochemical 542 markers levels and structure in older women with non-alcoholic fatty liver disease. J Bodyw<br>543 Mov Ther. 2020 Jul:24(3):154–60. Mov Ther. 2020 Jul;24(3):154–60.
- 544 23. Rezende REF, Duarte SMB, Stefano JT, Roschel H, Gualano B, De Sá Pinto AL, et al. 545 Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in 546 postmenopausal women with nonalcoholic fatty liver disease. Menopause. 2016 547 Aug;23(8):876–83.
- 548 24. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. 549 Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease 550 independent of weight loss. Gut. 2011 Sep 1;60(9):1278–83.
- 551 25. Cheng S, Ge J, Zhao C, Le S, Yang Y, Ke D, et al. Effect of aerobic exercise and diet on 552 liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized 553 controlled trial. Sci Rep. 2017 Nov 21;7(1):15952.
- 554 26. Pugh C, Sprung V, Aarons G, Richardson P, Shojaee-Moradie F, Umpleby A, et al. Exercise 555 training reverses endothelial dysfunction in nonalcoholic fatty liver disease. Am J Physiol-556 Heart Circ Physiol. 2014;307(9):H1298–306.

- 557 27. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise 558 effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. 559 Hepatology. 2012 Jun;55(6):1738–45.
- 560 28. Zhang HJ, He J, Pan LL, Ma ZM, Han CK, Chen CS, et al. Effects of Moderate and 561 Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. JAMA 562 Intern Med. 2016 Aug 1;176(8):1074.
- 563 29. Pugh C, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Margot Umpleby A, et al. 564 Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver 565 disease. Am J Physiol-Endocrinol Metab. 2013 Jul 1;305(1):E50–8.
- 566 30. Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, Soliman GS, et al. 567 Effects of High-Intensity Interval and Moderate-Intensity Continuous Aerobic Exercise on 568 Diabetic Obese Patients with Nonalcoholic Fatty Liver Disease: A Comparative Randomized 569 Controlled Trial. Medicine (Baltimore). 2020 Mar;99(10):e19471.
- 570 31. Takahashi A, Abe K, Usami K, Imaizumi H, Hayashi M, Okai K, et al. Simple Resistance 571 Exercise helps Patients with Non-alcoholic Fatty Liver Disease. Int J Sports Med. 2015 Jun 572 19;36(10):848–52.
- 573 32. Tutino V, De Nunzio V, Caruso M, Bonfiglio C, Franco I, Mirizzi A, et al. Aerobic Physical 574 Activity and a Low Glycemic Diet Reduce the AA/EPA Ratio in Red Blood Cell Membranes 575 of Patients with NAFLD. Nutrients. 2018 Sep 13;10(9):1299.
- 576 33. Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, et al. Exercise Reduces 577 Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a 578 Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3.
- 579 34. Sirisunhirun P, Bandidniyamanon W, Jrerattakon Y, Muangsomboon K, Pramyothin P, 580 Nimanong S, et al. Effect of a 12-week home-based exercise training program on aerobic 581 capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a 582 randomized controlled clinical trial. BMC Gastroenterol. 2022 Dec;22(1):66.
- 583 35. St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of 584 physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009 585 Jul;50(1):68–76.
- 586 36. Zelber-Sagi S. Effect of Resistance Training on Non-Alcoholic Fatty-Liver Disease a 587 Randomized-Clinical Trial. World J Gastroenterol. 2014;20(15):4382.
- 588 37. Marques CMM, Motta VF, Torres TS, Aguila MB, Mandarim-de-Lacerda CA. Beneficial 589 effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver 590 disease in high-fat fed C57BL/6 mice. Braz J Med Biol Res. 2010 May;43(5):467–75.
- 591 38. Schultz A, Mendonca LS, Aguila MB, Mandarim-de-Lacerda CA. Swimming training 592 beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol. 593 2012 May;64(4):273–82.

- 594 39. Silva RN, Bueno PG, Avó LRS, Nonaka KO, Selistre-Araújo HS, Leal AMO. Effect of 595 physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver 596 disease model in rats. Braz J Med Biol Res. 2014 Jul 25;47(9):746–52.
- 597 40. Gehrke N, Biedenbach J, Huber Y, Straub BK, Galle PR, Simon P, et al. Voluntary exercise 598 in mice fed an obesogenic diet alters the hepatic immune phenotype and improves 599 metabolic parameters – an animal model of life style intervention in NAFLD. Sci Rep. 2019 600 Mar 8;9(1):4007.
- 601 41. Gauthier MS, Couturier K, Charbonneau A, Lavoie JM. Effects of introducing physical 602 training in the course of a 16-week high-fat diet regimen on hepatic steatosis, adipose tissue 603 fat accumulation, and plasma lipid profile. Int J Obes. 2004 Aug;28(8):1064–71.
- 604 42. Linden MA, Fletcher JA, Morris EM, Meers GM, Laughlin MH, Booth FW, et al. Treating 605 NAFLD in OLETF Rats with Vigorous-Intensity Interval Exercise Training. Med Sci Sports 606 Exerc. 2015 Mar;47(3):556–67.
- 607 43. Sheldon RD, Laughlin MH, Rector RS. Reduced hepatic eNOS phosphorylation is 608 associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise 609 in hyperphagic OLETF rats. J Appl Physiol. 2014 May 1;116(9):1156–64.
- 610 44. Balducci S, Cardelli P, Pugliese L, D'Errico V, Haxhi J, Alessi E, et al. Volume-dependent 611 effect of supervised exercise training on fatty liver and visceral adiposity index in subjects 612 with type 2 diabetes The Italian Diabetes Exercise Study (IDES). Diabetes Res Clin Pract. 613 2015 Aug;109(2):355–63.
- 614 45. Shojaee-Moradie F, Cuthbertson DJ, Barrett M, Jackson NC, Herring R, Thomas EL, et al. 615 Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL<br>616 Production in NAFLD. J Clin Endocrinol Metab. 2016 Nov:101(11):4219–28. 616 Production in NAFLD. J Clin Endocrinol Metab. 2016 Nov;101(11):4219–28.
- 617 46. Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, et al. Modified 618 high-intensity interval training reduces liver fat and improves cardiac function in non-619 alcoholic fatty liver disease: a randomized controlled trial. Clin Sci. 2015 Dec 620 1;129(12):1097–105.
- 621 47. Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, et al. 622 Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome 623 Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol. 2021 624 Jun;12(6):e00371.
- 625 48. Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, et al. 626 Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the 627 OLETF rat model. Am J Physiol-Gastrointest Liver Physiol. 2011 May;300(5):G874–83.
- 628 49. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. 629 Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million 630 Adults. JAMA Intern Med. 2016 Jun 1;176(6):816.
- 631 50. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, et al. Daily 632 exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans 633 Tokushima Fatty rats. Am J Physiol-Gastrointest Liver Physiol. 2008 Mar;294(3):G619–26.

- 634 51. Fletcher JA, Meers GM, Laughlin MH, Ibdah JA, Thyfault JP, Rector RS. Modulating 635 fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric 636 restriction. Appl Physiol Nutr Metab. 2012 Dec;37(6):1054–62.
- 637 52. Borengasser SJ, Rector RS, Uptergrove GM, Morris EM, Perfield JW, Booth FW, et al. 638 Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of 639 Hepatic Steatosis in Hyperphagic OLETF Rats. J Nutr Metab. 2012;2012:1–12.
- 640 53. Cho J, Kim S, Lee S, Kang H. Effect of Training Intensity on Nonalcoholic Fatty Liver 641 Disease. Med Sci Sports Exerc. 2015 Aug;47(8):1624–34.
- 642 54. Cho J, Koh Y, Han J, Kim D, Kim T, Kang H. Adiponectin mediates the additive effects of 643 combining daily exercise with caloric restriction for treatment of non-alcoholic fatty liver. Int J 644 Obes. 2016 Nov;40(11):1760–7.
- 645 55. Dallak MA, Bin-Jaliah I, Albawardi A, Haidara MA, Sakr HF, Eid RA, et al. Swim exercise 646 training ameliorates hepatocyte ultrastructural alterations in rats fed on a high fat and sugar 647 diet. Ultrastruct Pathol. 2018 Mar 4;42(2):155–61.
- 648 56. Ghareghani P, Shanaki M, Ahmadi S, Khoshdel AR, Rezvan N, Meshkani R, et al. Aerobic 649 endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 650 dependent autophagy induction in high fat diet fed mice. Obes Res Clin Pract. 2018 651 Jan;12(1):80–9.
- 652 57. Gonçalves IO, Maciel E, Passos E, Torrella JR, Rizo D, Viscor G, et al. Exercise alters liver<br>653 mitochondria phospholipidomic profile and mitochondrial activity in non-alcoholic 653 mitochondria phospholipidomic profile and mitochondrial activity in non-alcoholic 654 steatohepatitis. Int J Biochem Cell Biol. 2014 Sep;54:163–73.
- 655 58. Gonçalves IO, Passos E, Diogo CV, Rocha-Rodrigues S, Santos-Alves E, Oliveira PJ, et al. 656 Exercise mitigates mitochondrial permeability transition pore and quality control 657 mechanisms alterations in nonalcoholic steatohepatitis. Appl Physiol Nutr Metab. 2016 658 Mar;41(3):298–306.
- 659 59. Gonçalves IO, Passos E, Rocha-Rodrigues S, Torrella JR, Rizo D, Santos-Alves E, et al. 660 Physical exercise antagonizes clinical and anatomical features characterizing Lieber-661 DeCarli diet-induced obesity and related metabolic disorders. Clin Nutr. 2015 662 Apr;34(2):241–7.
- 663 60. Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, et al. Exercise 664 Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation 665 in Mice. Cancers. 2020 May 29;12(6):1407.
- 666 61. Kristensen CM, Dethlefsen MM, Tøndering AS, Lassen SB, Meldgaard JN, Ringholm S, et 667 al. PGC-1  $\alpha$  in hepatic UPR during high-fat high-fructose diet and exercise training in mice.<br>668 Physiol Rep. 2018 Aug:6(15):e13819. 668 Physiol Rep. 2018 Aug;6(15):e13819.
- 669 62. La Fuente FP de, Quezada L, Sepúlveda C, Monsalves-Alvarez M, Rodríguez JM, Sacristán 670 C, et al. Exercise regulates lipid droplet dynamics in normal and fatty liver. Biochim Biophys 671 Acta BBA - Mol Cell Biol Lipids. 2019 Dec;1864(12):158519.

- 672 63. Linden MA, Fletcher JA, Morris EM, Meers GM, Kearney ML, Crissey JM, et al. Combining 673 metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in 674 OLETF rats. Am J Physiol-Endocrinol Metab. 2014 Feb 1;306(3):E300–10.
- 675 64. Linden MA, Sheldon RD, Meers GM, Ortinau LC, Morris EM, Booth FW, et al. Aerobic 676 exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis: Treating 677 western diet-induced NASH with exercise. J Physiol. 2016 Sep 15;594(18):5271–84.
- 678 65. Ok DP, Ko K, Bae JY. Exercise without dietary changes alleviates nonalcoholic fatty liver 679 disease without weight loss benefits. Lipids Health Dis. 2018 Dec;17(1):207.
- 680 66. Sakr HF, Abbas AM, Haidara MA. Swimming, but not vitamin E, ameliorates prothrombotic 681 state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. J Basic Clin 682 Physiol Pharmacol. 2018 Jan 26;29(1):61–71.
- 683 67. Simko V, Kelley RE, Dincsoy HP, Gimmon Z, Willmann K. Exercise in rats with liver injury 684 induced by carbon tetrachloride or bile duct obstruction. Blood cholic acid and liver 685 histology. Res Exp Med (Berl). 1982 Jun;181(2):135–45.
- 686 68. Tang H, Tan X, Zhu L, Qin K, Gao H, Bai H. Swimming prevents nonalcoholic fatty liver 687 disease by reducing migration inhibitory factor through Akt suppression and autophagy 688 activation. Am J Transl Res. 2019;11(7):4315–25.
- 689 69. Xia SF, Jiang YY, Qiu YY, Huang W, Wang J. Role of diets and exercise in ameliorating 690 obesity-related hepatic steatosis: Insights at the microRNA-dependent thyroid hormone 691 synthesis and action. Life Sci. 2020 Feb;242:117182.
- 692 70. Sato Y, Qiu J, Miura T, Kohzuki M, Ito O. Effects of Long-Term Exercise on Liver Cyst in 693 Polycystic Liver Disease Model Rats. Med Sci Sports Exerc. 2020 Jun;52(6):1272–9.



#### Identification of new studies via databases and registers

# Meta-analysis of human studies



# Meta-analysis of animal studies















